Featured news from NHIVNA
HIV-related news from NAM
Telaprevir and boceprevir boost sustained response rates for HIV/HCV coinfected
Liz Highleyman, 2012-03-07 05:10:00
Adding a first-generation hepatitis C virus (HCV) protease inhibitor to pegylated interferon/ribavirin dramatically increases the likelihood of 12-week sustained virological response to hepatitis C treatment among HIV/HCV coinfected people, researchers reported on Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Last year's approval of the first direct-acting hepatitis C drugs has ushered in a new era of treatment. The HCV protease inhibitors telaprevir (Incivo, Incivek) and boceprevir (Victrelis) are licensed in the US and Europe for HCV monoinfected patients in combination with pegylated interferon and ribavirin. Studies are ongoing for the coinfected population, a group that urgently needs better treatment options.
Source:1
